|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kollarova H, Machova L, Horakova D,
Janoutova G and Janout V: Epidemiology of esophageal cancer-an
overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech
Repub. 151:17–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bohanes P, Yang D, Chhibar RS, Labonte MJ,
Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, et al:
Influence of sex on the survival of patients with esophageal
cancer. J Clin Oncol. 30:2265–2272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steyerberg EW, Neville B, Weeks JC and
Earle CC: Referral patterns, treatment choices and outcomes in
locoregional esophageal cancer: A population-based analysis of
elderly patients. J Clin Oncol. 25:2389–2396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao P, Dai M, Chen W and Li N: Cancer
trends in China. Jpn J Clin Oncol. 40:281–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Xie X, Zhou C, Peng S, Rao D and Fu
J: Which factors are associated with actual 5-year survival of
oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg.
41:e7–e11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang L, Liu X, Chen Z, Jin Y, Heidbreder
CE, Kolokythas A, Wang A, Dai Y and Zhou X: MicroRNA-7 targets
IGF1R (insulin-like growth factor 1 receptor) in tongue squamous
cell carcinoma cells. Biochem J. 432:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soeda S, Ohyashiki JH, Ohtsuki K, Umezu T,
Setoguchi Y and Ohyashiki K: Clinical relevance of plasma miR-106b
levels in patients with chronic obstructive pulmonary disease. Int
J Mol Med. 31:533–539. 2013.PubMed/NCBI
|
|
9
|
Xiong Y, Zhang L, Holloway AK, Wu X, Su L
and Kebebew E: MiR-886-3p regulates cell proliferation and
migration and is dysregulated in familial non-medullary thyroid
cancer. PLoS One. 6:e247172011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ha TY: MicroRNAs in human diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shibuya H, Iinuma H, Shimada R, Horiuchi A
and Watanabe T: Clinicopathological and prognostic value of
microRNA-21 and microRNA-155 in colorectal cancer. Oncology.
79:313–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akao Y, Noguchi S, Iio A, Kojima K, Takagi
T and Naoe T: Dysregulation of microRNA-34a expression causes
drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer
Lett. 300:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tili E, Michaille JJ, Wernicke D, Alder H,
Costinean S, Volinia S and Croce CM: Mutator activity induced by
microRNA-155 (miR-155) links inflammation and cancer. Proc Natl
Acad Sci USA. 108:4908–4913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of
miR-486-5p contributes to tumor progression and metastasis by
targeting protumorigenic ARHGAP5 in lung cancer. Oncogene.
33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang G, Liu Z, Cui G, Wang X and Yang Z:
MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in
breast cancer cells. Tumour Biol. 35:11137–11145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang XP, Hou J, Shen XY, Huang CY, Zhang
XH, Xie YA and Luo XL: MicroRNA-486-5p, which is downregulated in
hepatocellular carcinoma, suppresses tumor growth by targeting
PIK3R1. FEBS J. 282:579–594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jing Q, Huang S, Guth S, Zarubin T,
Motoyama A, Chen J, Di Padova F, Lin SC, Gram H and Han J:
Involvement of microRNA in AU-rich element-mediated mRNA
instability. Cell. 120:623–634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo S, Bai H, Megyola CM, Halene S, Krause
DS, Scadden DT and Lu J: Complex oncogene dependence in
microRNA-125a-induced myeloproliferative neoplasms. Proc Natl Acad
Sci USA. 109:16636–16641. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhattacharyya S, Balakathiresan NS,
Dalgard C, Gutti U, Armistead D, Jozwik C, Srivastava M, Pollard HB
and Biswas R: Elevated miR-155 promotes inflammation in cystic
fibrosis by driving hyperexpression of interleukin-8. J Biol Chem.
286:11604–11615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lucotti S, Rainaldi G, Evangelista M and
Rizzo M: Fludarabine treatment favors the retention of miR-485-3p
by prostate cancer cells: Implications for survival. Mol Cancer.
12:522013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarver AL, French AJ, Borralho PM,
Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM,
Boardman LA, Cunningham JM, et al: Human colon cancer profiles show
differential microRNA expression depending on mismatch repair
status and are characteristic of undifferentiated proliferative
states. BMC Cancer. 9:4012009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo
X, Qin J, Chen J and Lu R: Identification of miR-508-3p and
miR-509-3p that are associated with cell invasion and migration and
involved in the apoptosis of renal cell carcinoma. Biochem Biophys
Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bentwich I, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H
and Zhou X: MicroRNA-222 regulates cell invasion by targeting
matrix metalloproteinase 1 (MMP1) and manganese superoxide
dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines.
Cancer Genomics Proteomics. 6:131–139. 2009.PubMed/NCBI
|
|
26
|
Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H
and Liu Z: MicroRNA-10b promotes migration and invasion through
KLF4 in human esophageal cancer cell lines. J Biol Chem.
285:7986–7994. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mathé EA, Nguyen GH, Bowman ED, Zhao Y,
Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, et
al: MicroRNA expression in squamous cell carcinoma and
adenocarcinoma of the esophagus: Associations with survival. Clin
Cancer Res. 15:6192–6200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hiyoshi Y, Kamohara H, Karashima R, Sato
N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M
and Baba H: MicroRNA-21 regulates the proliferation and invasion in
esophageal squamous cell carcinoma. Clin Cancer Res. 15:1915–1922.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feber A, Xi L, Luketich JD, Pennathur A,
Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA
expression profiles of esophageal cancer. J Thorac Cardiovasc Surg.
135:255–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ogawa R, Ishiguro H, Kuwabara Y, Kimura M,
Mitsui A, Katada T, Harata K, Tanaka T and Fujii Y: Expression
profiling of micro-RNAs in human esophageal squamous cell carcinoma
using RT-PCR. Med Mol Morphol. 42:102–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsushima K, Isomoto H, Kohno S and Nakao
K: MicroRNAs and esophageal squamous cell carcinoma. Digestion.
82:138–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma WJ, Lv GD, Tuersun A, Liu Q, Liu H,
Zheng ST, Huang CG, Feng JG, Wang X, Lin RY, et al: Role of
microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell
carcinoma. Mol Biol Rep. 38:3253–3260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsuchiya S, Fujiwara T, Sato F, Shimada Y,
Tanaka E, Sakai Y, Shimizu K and Tsujimoto G: MicroRNA-210
regulates cancer cell proliferation through targeting fibroblast
growth factor receptor-like 1 (FGFRL1). J Biol Chem. 286:420–428.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hong L, Han Y, Zhang H, Li M, Gong T, Sun
L, Wu K, Zhao Q and Fan D: The prognostic and chemotherapeutic
value of miR-296 in esophageal squamous cell carcinoma. Ann Surg.
251:1056–1063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ito T, Sato F, Kan T, Cheng Y, David S,
Agarwal R, Paun BC, Jin Z, Olaru AV, Hamilton JP, et al: Polo-like
kinase 1 regulates cell proliferation and is targeted by miR-593*
in esophageal cancer. Int J Cancer. 129:2134–2146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen J, Liu Z, Todd NW, Zhang H, Liao J,
Yu L, Guarnera MA, Li R, Cai L, Zhan M and Jiang F: Diagnosis of
lung cancer in individuals with solitary pulmonary nodules by
plasma microRNA biomarkers. BMC Cancer. 11:3742011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang
C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for
lung squamous cell carcinoma diagnosis and hsa-miR-31 for
prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ragusa M, Majorana A, Statello L, Maugeri
M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R,
Caltabiano R, et al: Specific alterations of microRNA transcriptome
and global network structure in colorectal carcinoma after
cetuximab treatment. Mol Cancer Ther. 9:3396–3409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bansal A, Lee IH, Hong X, Anand V, Mathur
SC, Gaddam S, Rastogi A, Wani SB, Gupta N, Visvanathan M, et al:
Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus
progression: A pilot cross-sectional, phase 2 biomarker study. Am J
Gastroenterol. 106:1055–1063. 2011. View Article : Google Scholar : PubMed/NCBI
|
